接受免疫治疗的肝细胞癌患者的心脏不良事件:合并症的影响与临床结局
这项回顾性研究纳入2017至2023年西班牙两家中心109例接受阿替利珠单抗-贝伐珠单抗、曲美木单抗-度伐利尤单抗或度伐利尤单抗一线治疗的晚期肝细胞癌患者,评估合并症与心脏不良事件及生存的关系。结果50.5%发生特殊关注不良事件,34%为免疫相关,7.3%发生主要不良心血管事件(MACE),含心肌炎3.7%。CARDIOSOR量表识别合并高血压和/或2型糖尿病者MACE风险升高(OR 5.07,p=0.034),早期心脏不良事件与更差OS独立相关(HR 3.38,p=0.04)。
要点
- 合并高血压和/或2型糖尿病者MACE风险升高,OR为5.07(p=0.034)。
- 早期心脏不良事件与更差总生存独立相关,HR为3.38(p=0.04)。
- 同时合并高血压和2型糖尿病者MACE发生率16.7%、治疗中断率25.9%。
核心结论
- 合并症尤其是高血压和2型糖尿病会放大MACE风险并影响治疗中断。
- CARDIOSOR量表是有价值的个体化风险评估工具,可指导定制治疗策略。
- 将心血管风险管理整合到肝细胞癌诊疗中对优化肿瘤和心血管结局至关重要。
研究设计与样本
- 回顾性研究,纳入2017至2023年西班牙两家医疗中心109例接受阿替利珠单抗-贝伐珠单抗、曲美木单抗-度伐利尤单抗或度伐利尤单抗一线治疗的肝细胞癌患者。
- 按合并症、不良事件发生情况和心脏风险(CARDIOSOR量表)对患者进行分层。
- 主要终点为影响治疗的不良事件和MACE的发生率及其与生存的关联。
主要发现
- 50.5%的患者发生特殊关注不良事件(AESI),其中34%被认为是免疫相关不良事件(irAE)。
- 7.3%的患者发生MACE,包括心肌炎(3.7%)。
- CARDIOSOR量表识别出合并高血压、2型糖尿病或两者兼有的患者MACE风险更高(OR:5.07,p=0.034)。
- 早期心脏不良事件与更差的总生存独立相关(HR:3.38,p=0.04)。
- 同时合并高血压和2型糖尿病的患者MACE发生率(16.7%)和治疗中断率(25.9%)更高。
关键数值与推荐
- CARDIOSOR量表识别合并高血压、2型糖尿病或两者兼有的患者MACE风险更高:OR为5.07(p=0.034)。
- 早期心脏不良事件与更差总生存独立相关:HR为3.38(p=0.04)。
- 同时合并高血压和2型糖尿病者MACE发生率为16.7%,治疗中断率为25.9%。
临床怎么用
- 作者认为CARDIOSOR量表是有价值的个体化风险评估工具,可指导定制治疗策略。
- 作者认为将心血管风险管理整合到肝细胞癌诊疗中对优化肿瘤和心血管结局至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy-based combinations have revolutionized the first-line treatment for advanced hepatocellular carcinoma (HCC), improving overall survival (OS). However, these therapies are associated with adverse events (AEs), particularly cardiological complications and major adverse cardiovascular events (MACE), which may adversely affect outcomes. The influence of comorbid conditions such as arterial hypertension (AHT) and type 2 diabetes mellitus (T2DM) on the incidence and prognosis of cardiological AEs in HCC patients remains understudied. METHODS: This retrospective study included 109 HCC patients treated with atezolizumab-bevacizumab, tremelimumab-durvalumab, or durvalumab as first-line therapy at two Spanish medical centers from 2017-2023. Patients were stratified by comorbidities, AE incidence, and cardiological risk (CARDIOSOR scale). The primary endpoints were the incidence of treatment-modifying AEs and MACE, and their association with survival. RESULTS: Among the cohort, 50.5 % experienced AEs of special interest (AESI), with 34 % considered immune-related (irAE). MACE occurred in 7.3 % of patients, including myocarditis (3.7 %). The CARDIOSOR scale identified a higher risk of MACE in patients with AHT, T2DM, or both (OR: 5.07, p = 0.034). Early cardiological AEs were independently associated with worse OS (HR: 3.38, p = 0.04). Patients with both AHT and T2DM exhibited higher rates of MACE (16.7 %) and treatment discontinuation (25.9 %). The CARDIOSOR scale effectively stratified patients into high-risk groups, correlating with increased MACE rates and poor survival outcomes. CONCLUSIONS: Comorbid conditions, particularly AHT and T2DM, amplify the risk of MACE and influence treatment discontinuation. The CARDIOSOR scale is a valuable tool for personalized risk assessment, guiding tailored therapeutic strategies. Integrating cardiovascular risk management into HCC care is crucial for optimizing both oncological and cardiovascular outcomes.
引用
- Fortuny M, García-Calonge M, Arrabal Ó, et al. Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes. Eur J Cancer. 2025. PMID: 40245453. doi:10.1016/j.ejca.2025.115404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。